Student Scholar Symposium Abstracts and Posters

Document Type


Publication Date

Fall 11-29-2023

Faculty Advisor(s)

Enrique Seoane-Vazquez


Background: Ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) are chimeric antigen receptor (CAR) T-cell therapies used to treat adult patients with relapsed or refractory multiple myeloma (rrMM) after at least four lines of therapy. However, no head-to-head clinical trials to compare them have been conducted.

Objective: To compare between CARTITUDE-1 and KarMMa clinical trials in terms of efficacy, safety, and patient characteristics.

Method: Overall response rate (ORR) and safety signals were compared using reporting odds ratios (RORs) with 95% confidence intervals (CIs) at p < 0.05. Overall survival (OS) and progression-free survival (PFS) were compared using the Kaplan–Meier method with a log-rank test. Patient characteristics were compared using the chi-square test. Statistical analyses were conducted using Microsoft Excel and R version 4.0.5.

Results: Statistically significant differences were observed between cilta-cel and ide-cel in terms of ORR, complete response (CR), OS, and PFS (p < 0.05). Partial response (PR) showed no statistically significant difference (p > 0.05). Ide-cel was significantly associated with higher incidences of any Grade ≥ 3 adverse events than cilta-cel. Cilta-cel on the other hand, was significantly associated with higher incidences of leukopenia, lymphopenia, and CRS Grade 1 & 2 than ide-cel (RORs > 1, p < 0.05). Penta-drug refractory showed a statistically significant difference between cilta-cel and ide-cel clinical trials.

Conclusion: This study found that cilta-cel is a superior treatment over ide-cel with better efficacy and less incidence of serious adverse events.


Presented at the Fall 2023 Student Scholar Symposium at Chapman University.